Literature DB >> 20958325

Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.

Marco Tartaglia1, Bruce D Gelb.   

Abstract

RAS GTPases control a major signaling network implicated in several cellular functions, including cell fate determination, proliferation, survival, differentiation, migration, and senescence. Within this network, signal flow through the RAF-MEK-ERK pathway-the first identified mitogen-associated protein kinase (MAPK) cascade-mediates early and late developmental processes controlling morphology determination, organogenesis, synaptic plasticity, and growth. Signaling through the RAS-MAPK cascade is tightly controlled; and its enhanced activation represents a well-known event in oncogenesis. Unexpectedly, in the past few years, inherited dysregulation of this pathway has been recognized as the cause underlying a group of clinically related disorders sharing facial dysmorphism, cardiac defects, reduced postnatal growth, ectodermal anomalies, variable cognitive deficits, and susceptibility to certain malignancies as major features. These disorders are caused by heterozygosity for mutations in genes encoding RAS proteins, regulators of RAS function, modulators of RAS interaction with effectors, or downstream signal transducers. Here, we provide an overview of the phenotypic spectrum associated with germline mutations perturbing RAS-MAPK signaling, the unpredicted molecular mechanisms converging toward the dysregulation of this signaling cascade, and major genotype-phenotype correlations.
© 2010 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20958325      PMCID: PMC3010252          DOI: 10.1111/j.1749-6632.2010.05790.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  187 in total

1.  Loose anagen hair syndrome and loose anagen hair.

Authors:  Antonella Tosti; Bianca Maria Piraccini
Journal:  Arch Dermatol       Date:  2002-04

Review 2.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

Review 3.  Getting a first clue about SPRED functions.

Authors:  Karin Bundschu; Ulrich Walter; Kai Schuh
Journal:  Bioessays       Date:  2007-09       Impact factor: 4.345

4.  The Noonan-CFC controversy.

Authors:  G Neri; M Zollino; J F Reynolds
Journal:  Am J Med Genet       Date:  1991-06-01

Review 5.  Neurofibromin: a general outlook.

Authors:  A B Trovó-Marqui; E H Tajara
Journal:  Clin Genet       Date:  2006-07       Impact factor: 4.438

6.  K-ras is essential for the development of the mouse embryo.

Authors:  K Koera; K Nakamura; K Nakao; J Miyoshi; K Toyoshima; T Hatta; H Otani; A Aiba; M Katsuki
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

7.  The Ullrich-Noonan syndrome (Turner phenotype).

Authors:  J J Nora; A H Nora; A K Sinha; R D Spangler; H A Lubs
Journal:  Am J Dis Child       Date:  1974-01

8.  Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal.

Authors:  B Marino; M C Digilio; A Toscano; A Giannotti; B Dallapiccola
Journal:  J Pediatr       Date:  1999-12       Impact factor: 4.406

9.  Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors:  S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

10.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

View more
  65 in total

1.  Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.

Authors:  Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

Review 2.  Developmental disease and cancer: biological and clinical overlaps.

Authors:  Alfonso Bellacosa
Journal:  Am J Med Genet A       Date:  2013-10-07       Impact factor: 2.802

Review 3.  14-3-3 Proteins: diverse functions in cell proliferation and cancer progression.

Authors:  Alyson K Freeman; Deborah K Morrison
Journal:  Semin Cell Dev Biol       Date:  2011-08-22       Impact factor: 7.727

Review 4.  BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.

Authors:  Pedro Madureira; Ramon Andrade de Mello
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

5.  Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

Authors:  Christian P Kratz; Suthee Rapisuwon; Helen Reed; Henrik Hasle; Philip S Rosenberg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-15       Impact factor: 3.908

6.  Comprehensive massive parallel DNA sequencing strategy for the genetic diagnosis of the neuro-cardio-facio-cutaneous syndromes.

Authors:  Ana Justino; Patrícia Dias; Maria João Pina; Sónia Sousa; Luís Cirnes; Ana Berta Sousa; José Carlos Machado; José Luis Costa
Journal:  Eur J Hum Genet       Date:  2014-06-04       Impact factor: 4.246

7.  RASopathies: Presentation at the Genome, Interactome, and Phenome Levels.

Authors:  Urska Pevec; Neva Rozman; Blaz Gorsek; Tanja Kunej
Journal:  Mol Syndromol       Date:  2016-04-21

8.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

9.  Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes.

Authors:  Simone Martinelli; Oliver H F Krumbach; Francesca Pantaleoni; Simona Coppola; Ehsan Amin; Luca Pannone; Kazem Nouri; Luciapia Farina; Radovan Dvorsky; Francesca Lepri; Marcel Buchholzer; Raphael Konopatzki; Laurence Walsh; Katelyn Payne; Mary Ella Pierpont; Samantha Schrier Vergano; Katherine G Langley; Douglas Larsen; Kelly D Farwell; Sha Tang; Cameron Mroske; Ivan Gallotta; Elia Di Schiavi; Matteo Della Monica; Licia Lugli; Cesare Rossi; Marco Seri; Guido Cocchi; Lindsay Henderson; Berivan Baskin; Mariëlle Alders; Roberto Mendoza-Londono; Lucie Dupuis; Deborah A Nickerson; Jessica X Chong; Naomi Meeks; Kathleen Brown; Tahnee Causey; Megan T Cho; Stephanie Demuth; Maria Cristina Digilio; Bruce D Gelb; Michael J Bamshad; Martin Zenker; Mohammad Reza Ahmadian; Raoul C Hennekam; Marco Tartaglia; Ghayda M Mirzaa
Journal:  Am J Hum Genet       Date:  2018-01-25       Impact factor: 11.025

10.  RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome.

Authors:  Nina Bögershausen; I-Chun Tsai; Esther Pohl; Pelin Özlem Simsek Kiper; Filippo Beleggia; E Ferda Percin; Katharina Keupp; Angela Matchan; Esther Milz; Yasemin Alanay; Hülya Kayserili; Yicheng Liu; Siddharth Banka; Andrea Kranz; Martin Zenker; Dagmar Wieczorek; Nursel Elcioglu; Paolo Prontera; Stanislas Lyonnet; Thomas Meitinger; A Francis Stewart; Dian Donnai; Tim M Strom; Koray Boduroglu; Gökhan Yigit; Yun Li; Nicholas Katsanis; Bernd Wollnik
Journal:  J Clin Invest       Date:  2015-08-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.